[{"id":"ce020719-ee60-4c78-aac1-c9da91de0268","acronym":"GIVEN","url":"https://clinicaltrials.gov/study/NCT07472478","created_at":"2026-03-28T01:39:49.899Z","updated_at":"2026-03-28T01:39:49.899Z","phase":"Phase 2","brief_title":"Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study)","source_id_and_acronym":"NCT07472478 - GIVEN","lead_sponsor":"Guangdong Provincial People's Hospital","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • Anfangning (garsorasib) • Yidafan (ivonescimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 03/15/2026","start_date":" 03/15/2026","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 03/31/2028","study_completion_date":" 03/31/2028","last_update_posted":"2026-03-16"},{"id":"7ee22b9c-eea6-45ba-bdc2-0adfd9a6a3e2","acronym":"","url":"https://clinicaltrials.gov/study/NCT07174908","created_at":"2025-09-20T07:06:19.138Z","updated_at":"2025-09-20T07:06:19.138Z","phase":"Phase 3","brief_title":"A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation","source_id_and_acronym":"NCT07174908","lead_sponsor":"InxMed (Shanghai) Co., Ltd.","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Tevimbra (tislelizumab-jsgr) • pemetrexed • Anfangning (garsorasib) • ifebemtinib (IN10018)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 09/01/2028","primary_completion_date":" 09/01/2028","study_txt":" Completion: 09/01/2030","study_completion_date":" 09/01/2030","last_update_posted":"2025-09-16"},{"id":"10d85d05-c74e-4575-b604-2c7e8a8ec8eb","acronym":"KEYNOTE-C15","url":"https://clinicaltrials.gov/study/NCT04585035","created_at":"2021-01-18T21:52:27.511Z","updated_at":"2025-02-25T16:10:41.752Z","phase":"Phase 1/2","brief_title":"Study to Evaluate D-1553 in Subjects With Solid Tumors","source_id_and_acronym":"NCT04585035 - KEYNOTE-C15","lead_sponsor":"InventisBio Co., Ltd","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Erbitux (cetuximab) • Anfangning (garsorasib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 180","initiation":"Initiation: 10/02/2020","start_date":" 10/02/2020","primary_txt":" Primary completion: 04/30/2024","primary_completion_date":" 04/30/2024","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2024-10-14"},{"id":"c2c2adc0-fff1-4c4f-86b0-e88c3d04d52a","acronym":"","url":"https://clinicaltrials.gov/study/NCT06435455","created_at":"2024-05-31T20:35:26.953Z","updated_at":"2024-07-02T16:34:59.697Z","phase":"Phase 1/2","brief_title":"GH21 Combined With D-1553 With Advanced Solid Tumors","source_id_and_acronym":"NCT06435455","lead_sponsor":"Suzhou Genhouse Bio Co., Ltd.","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Anfangning (garsorasib) • HBI-2376"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 126","initiation":"Initiation: 07/01/2024","start_date":" 07/01/2024","primary_txt":" Primary completion: 09/30/2027","primary_completion_date":" 09/30/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2024-05-31"},{"id":"82aa52d7-b360-425e-8654-41b803764529","acronym":"","url":"https://clinicaltrials.gov/study/NCT06166836","created_at":"2023-12-12T19:19:13.831Z","updated_at":"2024-07-02T16:35:22.973Z","phase":"Phase 1/2","brief_title":"a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors","source_id_and_acronym":"NCT06166836","lead_sponsor":"InxMed (Shanghai) Co., Ltd.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Anfangning (garsorasib) • ifebemtinib (IN10018)"],"overall_status":"Recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 10/12/2022","start_date":" 10/12/2022","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-01-18"},{"id":"dc5aa3f9-edce-4a48-85f5-65d5370191b9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05383898","created_at":"2022-05-20T18:58:28.262Z","updated_at":"2024-07-02T16:35:24.188Z","phase":"Phase 1/2","brief_title":"Study to Evaluate D-1553 in Subjects With Lung Cancer","source_id_and_acronym":"NCT05383898","lead_sponsor":"InventisBio Co., Ltd","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Anfangning (garsorasib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 225","initiation":"Initiation: 03/16/2021","start_date":" 03/16/2021","primary_txt":" Primary completion: 11/17/2023","primary_completion_date":" 11/17/2023","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2024-01-08"},{"id":"dbd3c702-b77e-4718-868a-acd3b8d02b5a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05379946","created_at":"2022-05-18T11:57:01.770Z","updated_at":"2024-07-02T16:35:32.883Z","phase":"Phase 1/2","brief_title":"Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors","source_id_and_acronym":"NCT05379946","lead_sponsor":"InventisBio Co., Ltd","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Anfangning (garsorasib) • ifebemtinib (IN10018)"],"overall_status":"Recruiting","enrollment":" Enrollment 92","initiation":"Initiation: 10/12/2022","start_date":" 10/12/2022","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2023-10-18"},{"id":"7d0590de-3903-42a9-9950-62db0c16814f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05492045","created_at":"2022-08-08T11:56:41.742Z","updated_at":"2024-07-02T16:35:49.654Z","phase":"Phase 1b/2","brief_title":"A Study to Evaluate D-1553 in Combination Therapy in Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05492045","lead_sponsor":"InventisBio Co., Ltd","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Anfangning (garsorasib)"],"overall_status":"Recruiting","enrollment":" Enrollment 144","initiation":"Initiation: 09/13/2022","start_date":" 09/13/2022","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-04-25"}]